Insulet first launched its Omnipod 5 patch-pump for people with Type 1 diabetes in 2022. Now, the device is also indicated for people with Type 2 diabetes ages 18 years and older.

Insulet Corporation, the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced its groundbreaking Omnipod 5 Automated Insulin Delivery System is ...

ACTON, Mass., August 26, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today ...

The insulin pump market is projected to reach $14bn in the same period, as per GlobalData analysis. Insulet also secured label expansion for Omnipod 5 device from the FDA allowing for its use in ...

Additionally, Insulet shared that it has two planned clinical trials for new algorithms for its platforms. One involves ...

ACTON, Mass., August 26, 2024--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced ...

The rapid adoption of the Omnipod 5 answered a question automated insulin delivery system manufacturers posed for years: with clear health benefits and payer coverage, why has pump adoption been so ...

Provides more choice and added convenience for Omnipod 5 users; Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ...

OAKVILLE, ON, April 7, 2025 /CNW/ - Insulet Corporation (PODD), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced that Omnipod 5 is now ...